本帖最后由 老马 于 2012-1-13 21:20 编辑
$ M6 j( z. ^$ U. ^3 K# N/ T7 V" f+ y; Y8 z% ^1 u! A
爱必妥和阿瓦斯丁的比较0 ]8 U2 l) J0 G4 V) T' i0 ?/ B
+ s, ]8 m) M6 {7 T: Q$ s. r% _4 h9 Jhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
5 U3 X. X! N" G
4 g5 e) Z/ b% R. S8 \$ m
/ d3 F% ^* }2 I! k# Y p
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
) \$ r6 ]. y; h( f( S1 q==================================================7 {/ D8 V0 O- q1 k. I
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)# s9 x8 q) W" c
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.6 M' T2 U" b6 _1 Z! v4 ~
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
: p2 N) z5 Q7 C6 q% ^% L- w
|
11011102001537 )
显身卡
8 x' v% k- w m/ W0 e
